Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HELIX BIOPHARMA (HBP:TSE) -- Ignore unavailable to you. Want to Upgrade?

To: thewiz who wrote (165)	11/13/1998 11:44:00 AM
From: burner	Read Replies (1) \| Respond to of 193

Biphasix presented to international scientists Helix Biopharma Corp HBP Shares issued 13,776,415 Nov 10 close $0.25 Wed 11 Nov 98 News Release An anonymous director reports The company's director of pharmaceutical research, Dr. Marianna Foldvari, will be presenting certain aspects of her research on the dermal and transdermal delivery of proteins using the Biphasix drug delivery system, at the American Association of Pharmaceutical Scientists annual meeting being held in San Francisco on Nov. 15 - 19. The Biphasix system is a unique, third generation, lipid-based microencapsulation delivery system which is capable of delivering a wide variety of pharmaceuticals of varying size, weight and solubility through the skin. Helix is concentrating its Biphasix development on the delivery of protein pharmaceuticals such as alpha interferon and insulin, as well as vaccines, via the dermal route with the objective of eliminating the need for injections. The company is actively promoting the Biphasix in Europe and North America to prospective commercial strategic partners to apply this technology to their existing compounds, as well as compounds under development.

To: thewiz who wrote (165)	1/28/1999 6:12:00 PM
From: burner	Respond to of 193

Helix transdermal vaccine successful; private financing Helix Biopharma Corp HBP Shares issued 13,776,415 Jan 27 close $0.42 Thu 28 Jan 99 News Release Dr. Marianna Foldvari reports Vaccines have been successfully delivered transdermally in mice using the Biphasix delivery system. These vaccine results complement the company's announcement in November 1998 that the Biphasix delivery system had been successfully used to deliver a large therapeutic protein, interferon-a, transdermally without the need for an injection. Furthermore, vaccine research using proprietary lipid-based delivery systems clearly showed that a single intranasal immunization generated a significant immune response in mice. When these immunized mice were exposed to the disease, they were 15 times more likely to survive than the mice which were not immunized. These results signify a major step forward in the development of the company's delivery systems for human and veterinary vaccine applications. The market for vaccines is currently in excess of $4-billion (U.S.) worldwide and growing at more than 10 per cent per year. With most vaccines and macromolecular therapeutics being delivered by injection, and more than 500 such large molecules and vaccines in the regulatory process in the United States, the Biphasix delivery system has the potential to replace or complement injections by taking molecules of varying sizes into and through the skin. Private Financing Two private investors have agreed to invest directly into Helix's subsidiary company, Sensium Technologies Inc. The investors have committed $750,000 for a 20 per cent minority interest in Sensium, to be paid in equal monthly instalments over the next 10 months, beginning January 1999. These funds will be used to accelerate the development of Sensium's proprietary advanced molecular sensor technology. This financing is the first step in management's plan to make Sensium autonomous and self-financing. This technology is being applied to the development of a miniaturized, self-contained biosensor with potential uses in medical diagnostics and pathogen detection.